298 related articles for article (PubMed ID: 32248831)
61. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
[TBL] [Abstract][Full Text] [Related]
62. Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late-onset Pompe disease.
Lika A; Andrinopoulou ER; van der Beek NAME; Rizopoulos D; van der Ploeg AT; Kruijshaar ME
J Inherit Metab Dis; 2023 Jul; 46(4):595-604. PubMed ID: 36966448
[TBL] [Abstract][Full Text] [Related]
63. A database for screening and registering late onset Pompe disease in Turkey.
Gokyigit MC; Ekmekci H; Durmus H; Karlı N; Koseoglu E; Aysal F; Kotan D; Ali A; Koytak PK; Karasoy H; Yaman A; Sengun İS; Sayin R; Tiftikcioglu BI; Soysal A; Tutkavul K; Bayrak AO; Kısabay A; Elci MA; Yayla V; Yılmaz İA; Ozdamar SE; Erdogan C; Tasdemir N; Serdaroglu Oflazer P;
Neuromuscul Disord; 2018 Mar; 28(3):262-267. PubMed ID: 29395671
[TBL] [Abstract][Full Text] [Related]
64. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.
de Vries JM; van der Beek NA; Hop WC; Karstens FP; Wokke JH; de Visser M; van Engelen BG; Kuks JB; van der Kooi AJ; Notermans NC; Faber CG; Verschuuren JJ; Kruijshaar ME; Reuser AJ; van Doorn PA; van der Ploeg AT
Orphanet J Rare Dis; 2012 Sep; 7():73. PubMed ID: 23013746
[TBL] [Abstract][Full Text] [Related]
65. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
Hundsberger T; Rösler KM; Findling O
J Neurol; 2014 Sep; 261(9):1684-90. PubMed ID: 24923245
[TBL] [Abstract][Full Text] [Related]
66. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
[TBL] [Abstract][Full Text] [Related]
67. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.
Lévesque S; Auray-Blais C; Gravel E; Boutin M; Dempsey-Nunez L; Jacques PE; Chenier S; Larue S; Rioux MF; Al-Hertani W; Nadeau A; Mathieu J; Maranda B; Désilets V; Waters PJ; Keutzer J; Austin S; Kishnani P
Orphanet J Rare Dis; 2016 Jan; 11():8. PubMed ID: 26809617
[TBL] [Abstract][Full Text] [Related]
68. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
[TBL] [Abstract][Full Text] [Related]
69. Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review.
Ditters IAM; van Kooten HA; van der Beek NAME; van der Ploeg AT; Huidekoper HH; van den Hout JMP
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759814
[TBL] [Abstract][Full Text] [Related]
70. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
[TBL] [Abstract][Full Text] [Related]
71. A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Dornelles AD; Junges APP; Pereira TV; Krug BC; Gonçalves CBT; Llerena JC; Kishnani PS; de Oliveira HA; Schwartz IVD
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768348
[TBL] [Abstract][Full Text] [Related]
72. Body composition and 6 minute walking ability in late-onset pompe disease patients after 9 years of enzyme replacement therapy.
Terzis G; Papadimas G; Krase A; Kontou E; Arnaoutis I; Papadopoulos C
Int J Neurosci; 2022 Jul; 132(7):699-705. PubMed ID: 33045893
[TBL] [Abstract][Full Text] [Related]
73. Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
Oliveira Santos M; Evangelista T; Conceição I
Neuromuscul Disord; 2018 Nov; 28(11):965-968. PubMed ID: 30314719
[TBL] [Abstract][Full Text] [Related]
74. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Lachmann RH; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):945-52. PubMed ID: 24906254
[TBL] [Abstract][Full Text] [Related]
75. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness.
Johnson K; Töpf A; Bertoli M; Phillips L; Claeys KG; Stojanovic VR; Perić S; Hahn A; Maddison P; Akay E; Bastian AE; Łusakowska A; Kostera-Pruszczyk A; Lek M; Xu L; MacArthur DG; Straub V
Orphanet J Rare Dis; 2017 Nov; 12(1):173. PubMed ID: 29149851
[TBL] [Abstract][Full Text] [Related]
76. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
Kuperus E; van der Meijden JC; In 't Groen SLM; Kroos MA; Hoogeveen-Westerveld M; Rizopoulos D; Martinez MYN; Kruijshaar ME; van Doorn PA; van der Beek NAME; van der Ploeg AT; Pijnappel WWMP
PLoS One; 2018; 13(12):e0208854. PubMed ID: 30532252
[TBL] [Abstract][Full Text] [Related]
77. Multisystem presentation of Late Onset Pompe Disease: what every consulting neurologist should know.
Jastrzębska A; Kostera-Pruszczyk A
Neurol Neurochir Pol; 2023; 57(2):143-150. PubMed ID: 36478346
[TBL] [Abstract][Full Text] [Related]
78. Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD).
Montagnese F; Granata F; Musumeci O; Rodolico C; Mondello S; Barca E; Cucinotta M; Ciranni A; Longo M; Toscano A
J Inherit Metab Dis; 2016 May; 39(3):391-398. PubMed ID: 26830551
[TBL] [Abstract][Full Text] [Related]
79. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
[TBL] [Abstract][Full Text] [Related]
80. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
